Andrea Pfeifer, AC Immune CEO
August 2, 2022 12:53 PM EDTUpdated 06:11 PM
Bioregnum
Pharma

How do you put a pos­i­tive spin on ug­ly da­ta? AC Im­mune gives it a shot in the wake of the lat­est crenezum­ab flop

Re­searchers spent close to a decade look­ing for signs that the failed Alzheimer’s drug crenezum­ab might work in a study that re­strict­ed it­self to a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times